fluorouracil has been researched along with Liver Dysfunction in 45 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The patient was treated with cetuximab and 5-fluorouracil at a below-guideline dose; however, portal vein thrombosis developed and led to death." | 9.41 | Portal vein thrombosis after cetuximab and 5-fluorouracil therapy in a patient with advanced colon cancer and decompensated cirrhosis: a case report and review of the literature. ( Guo, Y; Liu, F; Nian, J; Xu, Y; Yang, G, 2023) |
| "If tamoxifen was given together with adjuvant chemotherapy, no changes in liver function tests were detected." | 6.68 | Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
| " The patient was treated with cetuximab and 5-fluorouracil at a below-guideline dose; however, portal vein thrombosis developed and led to death." | 5.41 | Portal vein thrombosis after cetuximab and 5-fluorouracil therapy in a patient with advanced colon cancer and decompensated cirrhosis: a case report and review of the literature. ( Guo, Y; Liu, F; Nian, J; Xu, Y; Yang, G, 2023) |
| "Histological examinations revealed squamous cell carcinoma." | 5.37 | [A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil]. ( Fukui, T; Itoh, Y; Kawada, S; Takeda, H; Yoshioka, T, 2011) |
| "The pharmacokinetic profiles of tegafur, 5-FU and CDHP were altered by changes in the elimination rate of tegafur induced by a decrease in the conversion of tegafur to 5-FU." | 5.35 | Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats. ( Chikamoto, J; Kanie, S; Nagayama, S; Nishimura, T; Yoshisue, K, 2009) |
| "Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor." | 5.30 | Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999) |
| "Gemcitabine/capecitabine can be given at the standard dose in patients with severe hyperbilirubinemia, though the present data suggest that gemcitabine's activity may be limited due to poor intracellular activation." | 3.80 | Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. ( Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH, 2014) |
| "Bevacizumab (Avastin) in combination with intravenous 5-fluorouracil-based chemotherapy as first-line as well as second-line treatment of metastatic colorectal cancer improves survival." | 3.73 | Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. ( Gotlib, V; Khaled, S; Lapko, I; Mar, N; Saif, MW, 2006) |
| "A live attenuated vaccine virus variant of Rift Valley fever (RVF) virus was developed by passaging a human isolate in tissue culture under the influence of the mutagen 5-fluorouracil." | 3.68 | Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever. ( Baskerville, A; Hubbard, KA; Stephenson, JR, 1991) |
| "5 mg/kg of mitomycin-C (Mit-C) resulted in 70% (n = 20) and 71% (n = 14) mortality, respectively, from 2 to 7 days after perfusion, with extensive, patchy necrosis and infarction seen on histologic examination and markedly elevated levels of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) at 6 and 24 hours after perfusion." | 3.66 | Reversal of lethal, chemotherapeutically induced acute hepatic necrosis in rats by regenerating liver cytosol. ( Falk, JA; Falk, RE; Falk, W; Makowka, L; Miyazaki, M; Venturi, D, 1983) |
| "Nine patients with extensive bilateral hepatic metastases of colorectal cancer were treated with hepatic artery ligation and continuous infusion of 5-fluorouracil (5-FU)." | 3.65 | Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. ( Eilber, FR; Holmes, EC; Morton, DL; Ramming, KP; Sparks, FC, 1976) |
| "Patients with solid tumors were eligible if they were able to fit into one of three organ dysfunction cohorts: I, creatinine >1." | 2.71 | Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. ( Fleming, GF; Hong, AM; Meyerson, A; Ratain, MJ; Schilsky, RL; Schumm, LP; Vogelzang, NJ, 2003) |
| "If tamoxifen was given together with adjuvant chemotherapy, no changes in liver function tests were detected." | 2.68 | Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ, 1997) |
| "Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile." | 2.46 | Safety of capecitabine: a review. ( Marshall, JL; Mikhail, SE; Sun, JF, 2010) |
| " We present a concise review of cancer chemotherapy dosing in the setting of liver dysfunction." | 2.43 | Chemotherapy dosing in the setting of liver dysfunction. ( Eklund, JW; Mulcahy, MF; Trifilio, S, 2005) |
| "Histological examinations revealed squamous cell carcinoma." | 1.37 | [A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil]. ( Fukui, T; Itoh, Y; Kawada, S; Takeda, H; Yoshioka, T, 2011) |
| "The subjects were 13 colorectal cancer patients who had undergone resection of the primary tumor, and showed multiple, unresectable liver metastases and severe liver dysfunction." | 1.35 | [Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction]. ( Iizawa, H; Ikeda, E; Ishiyama, K; Mori, N; Saito, K; Sakurai, N; Sato, T; Suto, T; Takano, N, 2009) |
| "The pharmacokinetic profiles of tegafur, 5-FU and CDHP were altered by changes in the elimination rate of tegafur induced by a decrease in the conversion of tegafur to 5-FU." | 1.35 | Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats. ( Chikamoto, J; Kanie, S; Nagayama, S; Nishimura, T; Yoshisue, K, 2009) |
| "We report a case of rectal cancer with unresectable multiple liver metastases, which was worried about the transition from liver dysfunction to liver failure." | 1.35 | [A case of advanced rectal cancer with severe liver dysfunction due to multiple liver metastases]. ( Enomoto, M; Fujimori, Y; Higuchi, T; Iida, S; Ishiguro, M; Ishikawa, T; Kobayashi, H; Oda, G; Okazaki, S; Sugihara, K; Tsukamoto, S; Uetake, H; Yasuno, M, 2009) |
| "All patients died from neoplastic disease progression despite further chemotherapy at 6, 17 and 31 months following the diagnosis of NRH." | 1.34 | Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? ( Canon, JL; Ceratti, A; Gigot, JF; Horsmans, Y; Hubert, C; Humblet, Y; Machiels, JP; Rahier, J; Sempoux, C, 2007) |
| "Capecitabine (Xeloda) is a rationally designed oral, tumor-selective fluoropyrimidine carbamate aimed at preferential conversion to 5-fluorouracil (5-FU) within the tumor." | 1.30 | Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. ( Banken, L; Cassidy, J; Glynne-Jones, R; Goggin, T; Reigner, B; Roos, B; Schüller, J; Twelves, C; Utoh, M; Weidekamm, E, 1999) |
| "Diarrhea was the dose-limiting toxic effect and occurred more often in patients with abnormal pretreatment liver function." | 1.27 | Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (22.22) | 18.7374 |
| 1990's | 9 (20.00) | 18.2507 |
| 2000's | 19 (42.22) | 29.6817 |
| 2010's | 6 (13.33) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, F | 1 |
| Xu, Y | 1 |
| Yang, G | 1 |
| Guo, Y | 1 |
| Nian, J | 1 |
| Assayaghi, RM | 1 |
| Alabsi, AM | 1 |
| Swethadri, G | 1 |
| Ali, AM | 1 |
| Iwasa, S | 1 |
| Mayahara, H | 1 |
| Tanaka, T | 1 |
| Ito, Y | 1 |
| Joerger, M | 1 |
| Huitema, AD | 1 |
| Koeberle, D | 1 |
| Rosing, H | 1 |
| Beijnen, JH | 1 |
| Hitz, F | 1 |
| Cerny, T | 1 |
| Schellens, JH | 1 |
| Gillessen, S | 1 |
| Le Naourès, C | 1 |
| Guilloit, JM | 1 |
| Capovilla, M | 1 |
| Suto, T | 1 |
| Sato, T | 1 |
| Mori, N | 1 |
| Takano, N | 1 |
| Ishiyama, K | 1 |
| Sakurai, N | 1 |
| Saito, K | 1 |
| Iizawa, H | 1 |
| Ikeda, E | 1 |
| Viúdez, A | 1 |
| Rodríguez, J | 1 |
| Gil-Bazo, I | 1 |
| Bernardos García, C | 1 |
| Alarcón Del Agua, I | 1 |
| Casado Maestre, MD | 1 |
| Serrano Borrero, I | 1 |
| Alamo Martínez, JM | 1 |
| Grenader, T | 1 |
| Goldberg, A | 1 |
| Gabizon, A | 1 |
| Yoshisue, K | 1 |
| Kanie, S | 1 |
| Nishimura, T | 1 |
| Chikamoto, J | 1 |
| Nagayama, S | 1 |
| Higuchi, T | 1 |
| Ishikawa, T | 1 |
| Tsukamoto, S | 1 |
| Fujimori, Y | 1 |
| Oda, G | 1 |
| Okazaki, S | 1 |
| Ishiguro, M | 1 |
| Kobayashi, H | 1 |
| Iida, S | 1 |
| Uetake, H | 1 |
| Yasuno, M | 1 |
| Enomoto, M | 1 |
| Sugihara, K | 1 |
| Mikhail, SE | 1 |
| Sun, JF | 1 |
| Marshall, JL | 1 |
| Fukui, T | 1 |
| Itoh, Y | 1 |
| Yoshioka, T | 1 |
| Takeda, H | 1 |
| Kawada, S | 1 |
| Fleming, GF | 1 |
| Schilsky, RL | 1 |
| Schumm, LP | 1 |
| Meyerson, A | 1 |
| Hong, AM | 1 |
| Vogelzang, NJ | 1 |
| Ratain, MJ | 1 |
| Bojesen, AM | 1 |
| Nielsen, OL | 1 |
| Christensen, JP | 1 |
| Bisgaard, M | 1 |
| Innocenti, F | 1 |
| Danesi, R | 1 |
| Bocci, G | 1 |
| Natale, G | 1 |
| Del Tacca, M | 1 |
| Eklund, JW | 1 |
| Trifilio, S | 1 |
| Mulcahy, MF | 1 |
| Jang, JW | 1 |
| Bae, SH | 1 |
| Choi, JY | 1 |
| Oh, HJ | 1 |
| Kim, MS | 1 |
| Lee, SY | 1 |
| Kim, CW | 1 |
| Chang, UI | 1 |
| Nam, SW | 1 |
| Cha, SB | 1 |
| Lee, YJ | 1 |
| Chun, HJ | 1 |
| Choi, BG | 1 |
| Byun, JY | 1 |
| Yoon, SK | 1 |
| Gotlib, V | 1 |
| Khaled, S | 1 |
| Lapko, I | 1 |
| Mar, N | 1 |
| Saif, MW | 2 |
| Feng, YL | 1 |
| Ling, CQ | 1 |
| Chen, Z | 1 |
| Li, B | 1 |
| Gu, W | 1 |
| Hubert, C | 1 |
| Sempoux, C | 1 |
| Horsmans, Y | 1 |
| Rahier, J | 1 |
| Humblet, Y | 1 |
| Machiels, JP | 1 |
| Ceratti, A | 1 |
| Canon, JL | 1 |
| Gigot, JF | 1 |
| Muñoz Martín, AJ | 1 |
| Martínez Marín, V | 1 |
| Arranz Cózar, JL | 1 |
| Cabezón Gutiérrez, L | 1 |
| González del Val Subirats, R | 1 |
| García Alfonso, P | 1 |
| Saadati, H | 1 |
| Powis, G | 1 |
| Miyazaki, M | 1 |
| Makowka, L | 1 |
| Falk, RE | 1 |
| Falk, JA | 1 |
| Falk, W | 1 |
| Venturi, D | 1 |
| Bedikian, AY | 1 |
| Bodey, GP | 1 |
| Valdivieso, M | 1 |
| Burgess, MA | 1 |
| Daly, JM | 1 |
| Smith, G | 1 |
| Frazier, OH | 1 |
| Dudrick, SJ | 1 |
| Copeland, EM | 1 |
| Savrin, RA | 1 |
| Martin, EW | 1 |
| Moertel, CG | 1 |
| Fleming, TR | 1 |
| Macdonald, JS | 1 |
| Haller, DG | 1 |
| Laurie, JA | 1 |
| Uchino, J | 1 |
| Une, Y | 1 |
| Sato, Y | 1 |
| Gondo, H | 1 |
| Nakajima, Y | 1 |
| Sato, N | 1 |
| Hirvikoski, PP | 1 |
| Kumpulainen, EJ | 1 |
| Johansson, RT | 1 |
| Yamashita, F | 1 |
| Tanaka, M | 1 |
| Fukumori, K | 1 |
| Ando, E | 1 |
| Yano, Y | 1 |
| Kato, O | 1 |
| Yamamoto, H | 1 |
| Fukuda, H | 1 |
| Kusaba, T | 1 |
| Tanikawa, K | 1 |
| Sata, M | 1 |
| Hale, HL | 1 |
| Husband, JE | 1 |
| Gossios, K | 1 |
| Norman, AR | 1 |
| Cunningham, D | 1 |
| Twelves, C | 1 |
| Glynne-Jones, R | 1 |
| Cassidy, J | 1 |
| Schüller, J | 1 |
| Goggin, T | 1 |
| Roos, B | 1 |
| Banken, L | 1 |
| Utoh, M | 1 |
| Weidekamm, E | 2 |
| Reigner, B | 2 |
| Kimura, Y | 1 |
| Okuda, H | 1 |
| Blesch, K | 1 |
| Sikma, MA | 1 |
| Coenen, JL | 1 |
| Kloosterziel, C | 1 |
| Hasselt, BA | 1 |
| Ruers, TJ | 1 |
| Takemura, M | 1 |
| Ohta, Y | 1 |
| Shuto, T | 1 |
| Takemura, S | 1 |
| Ramming, KP | 1 |
| Sparks, FC | 1 |
| Eilber, FR | 1 |
| Holmes, EC | 1 |
| Morton, DL | 1 |
| Loo, TL | 1 |
| Benjamin, RS | 1 |
| Lu, K | 1 |
| Benvenuto, JA | 1 |
| Hall, SW | 1 |
| McKelvey, EM | 1 |
| Kemeny, NE | 1 |
| Hubbard, KA | 1 |
| Baskerville, A | 1 |
| Stephenson, JR | 1 |
| Iwamura, K | 1 |
| Markoff, N | 1 |
| Dumbadze, ND | 1 |
| Polishchuk, EI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for fluorouracil and Liver Dysfunction
| Article | Year |
|---|---|
Portal vein thrombosis after cetuximab and 5-fluorouracil therapy in a patient with advanced colon cancer and decompensated cirrhosis: a case report and review of the literature.
Topics: Cetuximab; Colonic Neoplasms; Fluorouracil; Humans; Liver Cirrhosis; Liver Diseases; Portal Vein; Po | 2023 |
Safety of capecitabine: a review.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2010 |
Chemotherapy dosing in the setting of liver dysfunction.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dos | 2005 |
Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs.
Topics: Antineoplastic Agents; Aspartic Acid; Bleomycin; Cisplatin; Cyclophosphamide; Doxorubicin; Fluoroura | 1982 |
Clinical pharmacokinetics of capecitabine.
Topics: Antacids; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Doceta | 2001 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes!
Topics: Actuarial Analysis; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dexamethasone; Fl | 1992 |
[Long-term therapy of liver diseases].
Topics: Aged; Anabolic Agents; Chronic Disease; Cortisone; Diet Therapy; Fatty Liver; Female; Fluorouracil; | 1972 |
9 trials available for fluorouracil and Liver Dysfunction
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bilirubin; Creatinine; Dose-Response Relationship, Dru | 2003 |
In vivo studies of Gallibacterium anatis infection in chickens.
Topics: Animals; Chickens; Fluorouracil; Immunocompromised Host; Immunosuppressive Agents; Liver; Liver Dise | 2004 |
A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2007 |
[Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient].
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Blood Urea Nitrogen; Chem | 2006 |
Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemical and Drug Induced Liver Injury; Chem | 1993 |
Chemohormonal therapy of unresectable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1993 |
Hepatic toxicity caused by adjuvant CMF/CNF in breast cancer patients and reversal by tamoxifen.
Topics: Acetyltransferases; Adult; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Antineoplastic Com | 1997 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes!
Topics: Actuarial Analysis; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dexamethasone; Fl | 1992 |
30 other studies available for fluorouracil and Liver Dysfunction
| Article | Year |
|---|---|
Liver Pathology in Rats Treated with Newcastle Disease Virus Strains AF2240 and V4-UPM.
Topics: Animals; Antimetabolites, Antineoplastic; Azoxymethane; Carcinogens; Fluorouracil; Liver Diseases; N | 2019 |
Ring-enhancing lesion associated with radiation-induced liver disease.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem | 2013 |
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycy | 2014 |
[A "lymph node" of the hepatic hilum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Intrahepatic; Cholecystectomy; Cisplatin | 2013 |
[Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; | 2009 |
Unresectable liver metastases from colorectal cancer and hepatic arterial infusion chemotherapy: how, when and to whom?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cathet | 2009 |
[Hepatic cystoadenocarcinoma. Differential diagnosis of hepatic cystic tumors].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcino | 2009 |
Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hum | 2009 |
Effect of dimethylnitrosamine-induced liver dysfunction on the pharmacokinetics of 5-fluorouracil after administration of S-1, an antitumour drug, to rats.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Chemical and Drug Induced Liver Injury; Dihydroura | 2009 |
[A case of advanced rectal cancer with severe liver dysfunction due to multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; Humans; Infusion | 2009 |
[A case of advanced esophageal cancer with multiple liver metastases accompanying poorly general conditions and serious liver dysfunctions, successfully treated using concurrent radiotherapy and chemotherapy with low-dose nedaplatin and 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2011 |
5-Fluorouracil catabolism to 5-fluoro-5,6-dihydrouracil is reduced by acute liver impairment in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Carbon Tetrachloride; Female; Fluorourac | 2005 |
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2006 |
Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Chemot | 2007 |
First-line treatment of advanced gastric cancer and hepatic dysfunction with oxaliplatin, 5-fluorouracil and cetuximab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2008 |
Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; F | 2008 |
Reversal of lethal, chemotherapeutically induced acute hepatic necrosis in rats by regenerating liver cytosol.
Topics: Acute Disease; Animals; Chemical and Drug Induced Liver Injury; Cytosol; Fluorouracil; Hyperthermia, | 1983 |
Phase I evaluation of oral tegafur.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio | 1983 |
Effects of systemic hyperthermia and intrahepatic infusion with 5-fluorouracil.
Topics: Animals; Dogs; Fluorouracil; Hot Temperature; Infusions, Intra-Arterial; Liver Diseases; Models, Bio | 1982 |
The relationship of the possible hepatic toxicity of chemotherapeutic drugs and carcinoembryonic antigen elevation.
Topics: Adenocarcinoma; Biopsy; Carcinoembryonic Antigen; Chemical and Drug Induced Liver Injury; Fluorourac | 1981 |
CT of calcified liver metastases in colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Calcinosis; Colorectal Neoplasms; Fluorouracil; Humans; Liver Disea | 1998 |
Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Colorectal Ne | 1999 |
Prevention by carp extract of myelotoxicity and gastrointestinal toxicity induced by 5-fluorouracil without loss of antitumor activity in mice.
Topics: Amino Acids; Animals; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Carps; Chemical and Dru | 1999 |
A breakthrough in cryosurgery.
Topics: Antimetabolites, Antineoplastic; Bronchial Fistula; Carcinoma; Cryosurgery; Fistula; Fluorouracil; H | 2002 |
[A case of unresectable gastric cancer complicated by a serious hepatic disorder and Virchow lymph node metastasis in which FP therapy and TS-1 administration were effective].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Colect | 1976 |
Metabolism and disposition of Baker's antifolate (NSC-139105), ftorafur (NSC-148958), and dichloroallyl lawsone (NSC-126771) in man.
Topics: Antineoplastic Agents; Diffusion; Fluorouracil; Folic Acid Antagonists; Humans; Kinetics; Liver Dise | 1978 |
Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever.
Topics: Animals; Fluorouracil; Humans; Liver Diseases; Rift Valley Fever; Rift Valley fever virus; Sheep; Sh | 1991 |
[Clinical studies of primary hepatic carcinoma].
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; Alkaline Phosphatase; Autopsy; Biopsy; Carcinoma, Hepat | 1971 |
[The effect of pyrogenal on the absorptive function of the liver during chemotherapy of patients with cancer of the stomach].
Topics: Fluorouracil; Humans; Liver; Liver Diseases; Pyrogens; Stomach Neoplasms | 1973 |